Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 296

1.

Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.

Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG, Cutts SM.

ACS Med Chem Lett. 2017 Apr 24;8(5):538-542. doi: 10.1021/acsmedchemlett.7b00090. eCollection 2017 May 11.

PMID:
28523107
2.

[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. French.

PMID:
28214007
3.

[Mitoxantrone role in treatment of primary progressive multiple sclerosis].

Pastuszak Ż, Stępień A, Tomczykiewicz K, Piusińska-Macoch R, Durka-Kęsy M.

Pol Merkur Lekarski. 2016 Jan;40(235):66-9. Review. Polish.

PMID:
26891441
4.

The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.

Macalou S, Robey RW, Jabor Gozzi G, Shukla S, Grosjean I, Hegedus T, Ambudkar SV, Bates SE, Di Pietro A.

Cell Mol Life Sci. 2016 May;73(9):1927-37. doi: 10.1007/s00018-015-2118-5. Epub 2015 Dec 26.

PMID:
26708291
5.

Mitoxantrone as a contributing factor in medication-related osteonecrosis of the jaws.

Bagan JV, Bagan L, Poveda R, Scully C.

Int J Oral Maxillofac Surg. 2016 Mar;45(3):377-9. doi: 10.1016/j.ijom.2015.09.025. Epub 2015 Oct 27.

PMID:
26516027
6.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.

PMID:
26044370
7.

The project data sphere initiative: accelerating cancer research by sharing data.

Green AK, Reeder-Hayes KE, Corty RW, Basch E, Milowsky MI, Dusetzina SB, Bennett AV, Wood WA.

Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.

8.

Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group.

Cancer. 2015 Jul 15;121(14):2393-9. doi: 10.1002/cncr.29389. Epub 2015 Apr 6.

9.

[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].

Shibazaki M, Sumi M, Takeda W, Kirihara T, Kurihara T, Sato K, Ueki T, Hiroshima Y, Ueno M, Ichikawa N, Mori Y, Kobayashi H.

Rinsho Ketsueki. 2014 Aug;55(8):970-4. Japanese.

PMID:
25186488
10.

Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells.

Jendželovská Z, Jendželovský R, Hiľovská L, Kovaľ J, Mikeš J, Fedoročko P.

Toxicol In Vitro. 2014 Oct;28(7):1259-73. doi: 10.1016/j.tiv.2014.06.011. Epub 2014 Jun 30.

PMID:
24994473
11.

Nanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cells.

Toh TB, Lee DK, Hou W, Abdullah LN, Nguyen J, Ho D, Chow EK.

Mol Pharm. 2014 Aug 4;11(8):2683-91. doi: 10.1021/mp5001108. Epub 2014 Jun 4.

12.

Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.

Pedrazzoli P, Martinelli G, Gianni AM, Da Prada GA, Ballestrero A, Rosti G, Frassineti GL, Aieta M, Secondino S, Cinieri S, Fedele R, Bengala C, Bregni M, Grasso D, De Giorgi U, Lanza F, Castagna L, Bruno B, Martino M; of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO) – Sezione Tumori Solidi.

Biol Blood Marrow Transplant. 2014 Apr;20(4):501-6. doi: 10.1016/j.bbmt.2013.12.569. Epub 2013 Dec 27.

13.
14.

Application of Fenton, photo-Fenton, solar photo-Fenton, and UV/H2O2 to degradation of the antineoplastic agent mitoxantrone and toxicological evaluation.

Cavalcante RP, da Rocha Sandim L, Bogo D, Barbosa AM, Osugi ME, Blanco M, de Oliveira SC, de Fatima Cepa Matos M, Machulek A Jr, Ferreira VS.

Environ Sci Pollut Res Int. 2013 Apr;20(4):2352-61. doi: 10.1007/s11356-012-1110-y. Epub 2012 Aug 12.

PMID:
22886782
15.

Breast cancer, side population cells and ABCG2 expression.

Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TW, Meeson AP.

Cancer Lett. 2012 Oct 1;323(1):97-105. doi: 10.1016/j.canlet.2012.03.041. Epub 2012 Apr 17.

16.

Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result.

Orthmann A, Zeisig R, Süss R, Lorenz D, Lemm M, Fichtner I.

Pharm Res. 2012 Jul;29(7):1949-59. doi: 10.1007/s11095-012-0723-7. Epub 2012 Mar 8.

PMID:
22399388
17.

Molecular pathogenesis of secondary acute promyelocytic leukemia.

Joannides M, Mays AN, Mistry AR, Hasan SK, Reiter A, Wiemels JL, Felix CA, Coco FL, Osheroff N, Solomon E, Grimwade D.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011045. doi: 10.4084/MJHID.2011.045. Epub 2011 Oct 24.

18.

Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.

Ni Z, Bikadi Z, Shuster DL, Zhao C, Rosenberg MF, Mao Q.

Biochemistry. 2011 Sep 20;50(37):8057-66. doi: 10.1021/bi200573t. Epub 2011 Aug 26.

19.

Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data.

Kim J, Lee J, Chang E, Suh K, Lee C, Jee J, Shin H.

J Breast Cancer. 2011 Mar;14(1):39-45. doi: 10.4048/jbc.2011.14.1.39. Epub 2011 Mar 31.

20.

Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

Pal SK, Twardowski P, Sartor O.

Clin Interv Aging. 2010 Dec 3;5:395-402. doi: 10.2147/CIA.S14570. Review.

Supplemental Content

Loading ...
Support Center